A ‘Global Reference’ Comparator for Biosimilar Development

Estudios puentes entre biologicos de referencia en pais de origen y pais de sometimiento: Son siempre necesarios? https://t.co/PxzebuG2GK

RT @AnnaRoseWelch: FDA's Gottlieb looking into eliminating bridging studies, which could streamline #biosimilar development. That's kind of…

RT @AnnaRoseWelch: FDA's Gottlieb looking into eliminating bridging studies, which could streamline #biosimilar development. That's kind of…

FDA's Gottlieb looking into eliminating bridging studies, which could streamline #biosimilar development. That's kind of big news. https://t.co/LkNoClkWMV Read the original call for global ref products here: https://t.co/h96J8JslmG

Bridging studies between local and foreign versions of an originator biologic : Not legally required! A very good…https://t.co/WJNiXUNNsE

RT @avalerehealth: Looking for more on #biosimilars? Check out Gillian Woollet's research that was published in BioDrugs! https://t.co/5tv…

Looking for more on #biosimilars? Check out Gillian Woollet's research that was published in BioDrugs! https://t.co/5tvCTOpwlQ

RT @AnnemarieVtW: A ‘Global Reference’ Comparator for #Biosimilar Development | #biosimilars SpringerLink https://t.co/SKi03F1bxP